Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Lung Diseases, Bronchitis, Chronic
Interventions: Avelox (Moxifloxacin, BAY12-8039), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 1,404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 11
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 7 more

Conditions: HIV Infections
Interventions: Project ABLE; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older · Male only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Cesarean Section, Infection
Interventions: Cefazolin (Timing of Antibiotic Prophylaxis); Drug
Lead sponsor: MemorialCare; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Common Cold, Gastroenteritis
Interventions: dietary supplement--echinacea, propolis, and vitamin c; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 3 Years to 6 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Respiratory Syncytial Virus Infections
Interventions: Not listed
Lead sponsor: MedImmune LLC; Industry
Eligibility: 1 Month to 6 Months
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 59
States / cities: Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more

Conditions: CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions: Letermovir Pill, blood draw; Drug · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 12 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Minneapolis, Minnesota • New York, New York

Conditions: BK Virus Infection
Interventions: Ciprofloxacin, placebo; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematologic Malignancy, Myeloproliferative Disorder
Interventions: Isavuconazole; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Vulvar Diseases, HPV Infection, Vulvar HSIL, Pre-Cancerous Dysplasia, HPV Disease, VIN, Usual Type, VIN 2 of Usual Type, VIN 3 of Usual Type, Vin II, Vin III, VIN Grade 2, VIN Grade 3, High Grade Intraepithelial Neoplasia
Interventions: Artesunate ointment, Placebo ointment; Drug
Lead sponsor: Frantz Viral Therapeutics, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 5
States / cities: Fort Myers, Florida • Indianapolis, Indiana • Cleveland, Ohio + 1 more

Conditions: HIV Infections, Opioid Use, Trauma, Psychological
Interventions: Expressive Writing, Contingency Management; Behavioral
Lead sponsor: Drexel University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions: Pentamidine isethionate, Dapsone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 14
States / cities: San Francisco, California • Denver, Colorado • Wilmington, Delaware + 10 more

Conditions: Antibiotic Side Effect, Eyelid; Wound, Eyelid Diseases, Surgical Wound Infection, Surgical Wound, Recent, Surgical Incision, Skin Cancer Face, Antibiotic Allergy, Surgical Site Infection
Interventions: Topical Antibiotic Product, Topical Non-Antibiotic Ointment; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV/AIDS, HIV Prevention
Interventions: Tenofovir douche; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 2
States / cities: Baltimore, Maryland • Pittsburgh, Pennsylvania

Conditions: COVID-19
Interventions: Hydroxychloroquine, Placebo oral tablet; Drug
Lead sponsor: Adrian Hernandez; Other
Eligibility: 18 Years and older
Enrollment: 1,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 34
States / cities: Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Valacyclovir hydrochloride, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 21
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 16 more

Conditions: HIV Infection, Human Immunodeficiency Virus
Interventions: PolyEnv1 vaccine; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: COVID-19
Interventions: mRNA-1283.222, mRNA-1273.222, mRNA-1283.815, mRNA-1273.815; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 13,553 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 161
States / cities: Huntsville, Alabama • Vestavia Hills, Alabama • Chandler, Arizona + 129 more

Conditions: Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Oral Complications, Ovarian Cancer, Pain, Sarcoma
Interventions: management of therapy complications, pain therapy; Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Coronavirus Disease 2019 (COVID-19)
Interventions: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 14
States / cities: Bradenton, Florida • St. Petersburg, Florida • Mason City, Iowa + 11 more

Conditions: Urinary Tract Infections
Interventions: Cranberry juice cocktail; Drug
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: New Haven, Connecticut • Seattle, Washington

Conditions: HIV-1-infection
Interventions: PrEPsmart mobile app, Truvada; Device · Drug
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Candida Auris Infection, Colonization, Asymptomatic
Interventions: Povidone Iodine Topical; Drug
Lead sponsor: Mary K Hayden; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Chicago, Illinois • Hinsdale, Illinois

Conditions: HIV Infections
Interventions: Infección de Amor (Infectious Love); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: HIV Infections
Interventions: education; Behavioral
Lead sponsor: Public Health Solutions; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

Culturally-Tailored HIV Risk Reduction for African-American MSM

Trial Comparing the Optimal Timing of Antibiotic Prophylaxis at the Time of Cesarean Delivery

Echinacea, Propolis and Vitamin C for URI Prevention in Preschoolers

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Ciprofloxacin for Prevention of BK Infection

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

Phase II Study of Artesunate Ointment for the Treatment of Vulvar High Grade Squamous Intraepithelial Lesions (Vulvar HSIL, VIN2/3)

Trauma Intervention to Optimize PrEP Among Women Who Inject Drugs

A Study of Pentamidine Plus Dapsone in the Prevention of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients Who Cannot Take Trimethoprim or Sulfonamides

Topical Antibiotic Prophylaxis for Eyelids

Tenofovir Rectal Douche to Prevent HIV Transmission

Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)

Cranberry Juice for the Prevention of Recurrent Urinary Tract Infections

PrEPsmart 2-1-1 Pilot

Nasal Antisepsis for C. Auris Prevention

Impact of a Telenovela/Soap Opera for HIV Prevention in Latinas

Online HIV Prevention Vignette Evaluation